December 2014
December 2014
Atlante Seed
Bologna, Italy
Medtech
Ongoing
Cellply is bringing to market an innovative, fully automated, walkaway analytical platform for profiling of immune cell function. The platform offers a dramatically improved understanding of cell function at the single cell level with applicability across all stages of R&D into clinical development and manufacturing for immune cell therapy and other immunotherapies.
The analytic platform allows to create 10’s of thousands of miniature co-cultures and characterize single immune cells through multiple assays run in parallel, as cytotoxicity, serial killing, cytokines, antigen expression and immunophenotypes.
The Co-Culture Array technology allows the observation of thousands of individual immune cells interacting within biologically-relevant multi-cellular contexts.
Atlante Seed initially invested in February 2014.